Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Phase 1 Study to Investigate the Effect of Obicetrapib on Lipoprotein Metabolism.

NCT05972278 is registered in ClinicalTrials.gov with NewAmsterdam Pharma as lead sponsor.

NCT NCT05972278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05972278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Phase 1 Study to Investigate the Effect of Obicetrapib on Lipoprotein Metabolism.
Lead sponsor
NewAmsterdam Pharma
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 1, 2023
Completion date
October 14, 2024
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lipid metabolism